Drug Trial News

RSS

Arena Pharmaceuticals presents data from its Phase 3 trial of LOrcaserin

Arena Pharmaceuticals, Inc. reported today data from the pivotal BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) Phase 3 trial that demonstrate improvements in patients' body composition, cardiovascular risk factors and quality of life. These findings add to the previously announced top-line BLOSSOM data that showed highly significant weight loss with lorcaserin over one year of treatment in 4,008 patients.

28 Oct 2009

Data from Phase II clinical trial of NKTR-118 presented

Data from a phase II study demonstrated that oral NKTR-118 improved lower gastrointestinal dysfunction by increasing the frequency of bowel movements in patients with opioid-induced constipation, while simultaneously preserving opioid-mediated analgesia.

28 Oct 2009

Recruitment of Phase II trial of TB-402 completed ahead of schedule

ThromboGenics NV and co-development partner BioInvent International announce that they have completed recruitment of their Phase II trial of TB-402 ahead of schedule.

28 Oct 2009

POZEN announces Phase I study results of PA65020

POZEN Inc. announced today the results of a Phase I study that showed a novel, investigational combination of enteric-coated aspirin (EC-ASA) and immediate-release omeprazole known as PA65020, is associated with a significantly decreased risk of GI mucosal damage compared to analgesic doses (650 mg twice daily) of over-the-counter enteric-coated aspirin (EC-ASA) in healthy adults treated for one month.

28 Oct 2009

Mirafit fbcx reduces human body absorption of consumed fat

A scientific study to be presented today at the annual meeting of The Obesity Society will confirm significant weight loss using the pill mirafit fbcx®. Dr. K-L Catherine Jen and Dr. Joseph Artiss, principals at ArtJen Complexus USA, LLC, will present these clinical study findings today, October 27, at The Obesity Society 2009 annual scientific meeting at the Marriott Wardman Park Hotel in Washington, D.C., The Obesity Society's 27th annual scientific meeting.

28 Oct 2009

Isotechnika Pharma reports voclosporin Phase 2/3 clinical trial results at the AAO meeting

Isotechnika Pharma Inc. today announced that results of the international Phase 2/3 clinical trials studying voclosporin, conducted by its partner Lux Biosciences, were the subject of two podium presentations at the American Association of Ophthalmology (AAO) meeting and of a presentation at the satellite meeting of the American Uveitis Society (AUS) in San Francisco, October 24-27.

27 Oct 2009

Hyperion Therapeutics enrolls first patient in HPN-100 phase III clinical trial for urea cycle disorders

Hyperion Therapeutics today announced that the first patient has been enrolled in its pivotal phase III clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate). The 4-week, multi-center, randomized, double-blind, cross-over study is designed to evaluate the non-inferiority of glycerol phenylbutyrate to BUPHENYL® (sodium phenylbutyrate) Tablets and Powder in adults with urea cycle disorders.

27 Oct 2009

NeoPharma submits a Phase II protocol to the FDA for its liposome entrapped docetaxel study

NeoPharm, Inc. today announced that it has submitted a Phase II protocol to the FDA for the study of liposome entrapped docetaxel (LE-DT), a novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere®, for locally advanced or metastatic pancreatic cancer patients.

27 Oct 2009

First Japanese patient treated in Celsion’s global Phase III ThermoDox HEAT trial

Celsion Corporation and Yakult Honsha Co., Ltd. announced today that the first patient has been enrolled and treated in Japan as part of Celsion’s global Phase III ThermoDox HEAT trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer.

27 Oct 2009

Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation

Alkermes, Inc. today announced the initiation of a phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the opioid agonist effects on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled study will assess the safety, tolerability and pharmacokinetic effects of a single oral administration of five doses of ALKS 37 in approximately 40 healthy volunteers.

27 Oct 2009

Interim results from FREEDOM study announced by NxStage Medical

NxStage Medical, Inc., a leading manufacturer of innovative dialysis products, today announced the latest interim results from its ongoing FREEDOM study. The FREEDOM data will be presented in posters at the American Society of Nephrology (ASN) Renal Week 2009, from October 27th to November 1st in San Diego.

27 Oct 2009

ImmunoCellular Therapeutics presents additional data from its ICT-107 Phase I clinical trial

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is focused on the development of novel immune-based cancer therapies, today announced additional data from its Phase I clinical trial evaluating ICT-107, the Company’s dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme (GBM).

27 Oct 2009

Champions Biotechnology obtains global rights to Tel Aviv University's TAR-1 compound

Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has established an exclusive licensing agreement with Ramot at Tel Aviv University Ltd., Tel Aviv University's wholly owned technology transfer company.

27 Oct 2009

Positive results from Phase II clinical trial of INT-747 announced

Intercept Pharmaceuticals, Inc., today announced positive results from a 165 patient, placebo controlled, double-blind Phase II clinical trial of INT-747 in patients with primary biliary cirrhosis (PBC).

27 Oct 2009

Positive results from Logical Therapeutics' Phase I/II LT-NS001 clinical study

Logical Therapeutics, Inc., a Waltham, MA-based biopharmaceutical company announced today the positive results of a Phase I/II clinical trial evaluating the gastrointestinal (GI) safety of its investigational drug LT-NS001, the first of a new class of bio-activated prodrugs being developed for the chronic treatment of arthritic conditions.

27 Oct 2009

PolyMedix completes second successful clinical study of PMX-60056

PolyMedix, Inc. (http://polymedix.com), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders, has completed a second successful clinical study of its anticoagulant reversing agent, PMX-60056.

27 Oct 2009

Lexicon Pharmaceuticals reports fiscal 2009 third-quarter results and updates of its clinical trials

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and nine months ended September 30, 2009.

27 Oct 2009

Phase 2 clinical study of PEG-Interferon lambda commenced

ZymoGenetics, Inc. today announced the initiation of a Phase 2 clinical trial of PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus (HCV) infection (the “EMERGE” study).

27 Oct 2009

LX211 may become the first approved oral treatment for modifying the course of uveitis

An experimental drug, LX211 (LUVENIQ - oral voclosporin), may become the first approved oral treatment capable of modifying the course of uveitis, a group of serious eye conditions inevitably associated with either severe vision loss or substantial morbidity from steroid use.

27 Oct 2009

Phase 3 trial results of Horizon Therapeutics's HZT-501 presented at the ACG meeting

Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today presented an analysis from two pivotal Phase 3 trials (REDUCE-1 and REDUCE-2) evaluating its lead investigational compound HZT-501, a combination of ibuprofen with high-dose famotidine.

27 Oct 2009

Drug Trial News

Arena Pharmaceuticals presents data from its Phase 3 trial of LOrcaserin

Data from Phase II clinical trial of NKTR-118 presented

Recruitment of Phase II trial of TB-402 completed ahead of schedule

POZEN announces Phase I study results of PA65020

Mirafit fbcx reduces human body absorption of consumed fat

Isotechnika Pharma reports voclosporin Phase 2/3 clinical trial results at the AAO meeting

Hyperion Therapeutics enrolls first patient in HPN-100 phase III clinical trial for urea cycle disorders

NeoPharma submits a Phase II protocol to the FDA for its liposome entrapped docetaxel study

First Japanese patient treated in Celsion’s global Phase III ThermoDox HEAT trial

Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation

Interim results from FREEDOM study announced by NxStage Medical

ImmunoCellular Therapeutics presents additional data from its ICT-107 Phase I clinical trial

Champions Biotechnology obtains global rights to Tel Aviv University's TAR-1 compound

Positive results from Phase II clinical trial of INT-747 announced

Positive results from Logical Therapeutics' Phase I/II LT-NS001 clinical study

PolyMedix completes second successful clinical study of PMX-60056

Lexicon Pharmaceuticals reports fiscal 2009 third-quarter results and updates of its clinical trials

Phase 2 clinical study of PEG-Interferon lambda commenced

LX211 may become the first approved oral treatment for modifying the course of uveitis

Phase 3 trial results of Horizon Therapeutics's HZT-501 presented at the ACG meeting

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News